Adam Watson

Adam Watson

Auto-generated profile, based on publicly available information

Adam Watson

19MeCo Diagnostics, San Diego, California

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Biomaterials
Verified
Journal Article
Closed access
NPNitish Peela
Nitish Peela
FSFeba S. Sam
Feba S. Sam
WCWayne Christenson
Wayne Christenson
DTDanh Truong
Danh Truong
AWAdam W. Watson
Adam W. Watson
MNMehdi Nikkhah
Mehdi Nikkhah

8 October 2019 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
JPJulieann I. Puleo
Julieann I. Puleo
SPSara S. Parker
Sara S. Parker
MRMackenzie R. Roman
Mackenzie R. Roman
AWAdam W. Watson
Adam W. Watson
KEKiarash Rahmani Eliato
Kiarash Rahmani Eliato
Ghassan (Gus) MouneimneGhassan (Gus) Mouneimne
Ghassan (Gus) Mouneimne
The mechanical properties of a cell’s microenvironment influence many aspects of cellular behavior, including cell migration. Durotaxis, the migration toward increasing matrix stiffness, has been implicated in processes ranging from development to cancer. During durotaxis, mechanical stimulation by matrix rigidity leads to directed migration. Studies suggest that cells sense mechanical stimuli, or mechanosense, through the acto-myosin cytoskeleton at focal adhesions (FAs); however, FA actin cytoskeletal remodeling and its role in mechanosensing are not fully understood. Here, we show that the Ena/VASP family member, Ena/VASP-like (EVL), polymerizes actin at FAs, which promotes cell-matrix adhesion and mechanosensing. Importantly, we show that EVL regulates mechanically directed motility, and that suppression of EVL expression impedes 3D durotactic invasion. We propose a model in which EVL-mediated actin polymerization at FAs promotes mechanosensing and durotaxis by maturing, and thus reinforcing, FAs. These findings establish dynamic FA actin polymerization as a central aspect of mechanosensing and identify EVL as a crucial regulator of this process.

30 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMarco Padilla-Rodriguez
Marco Padilla-Rodriguez
SPSara S. Parker
Sara S. Parker
DADeanna G. Adams
Deanna G. Adams
TWThomas Westerling
Thomas Westerling
JPJulieann I. Puleo
Julieann I. Puleo
Ghassan (Gus) MouneimneGhassan (Gus) Mouneimne
Ghassan (Gus) Mouneimne
Estrogen promotes growth of estrogen receptor-positive (ER+) breast tumors. However, epidemiological studies examining the prognostic characteristics of breast cancer in postmenopausal women receiving hormone replacement therapy reveal a significant decrease in tumor dissemination, suggesting that estrogen has potential protective effects against cancer cell invasion. Here, we show that estrogen suppresses invasion of ER+ breast cancer cells by increasing transcription of the Ena/VASP protein, EVL, which promotes the generation of suppressive cortical actin bundles that inhibit motility dynamics, and is crucial for the ER-mediated suppression of invasion in vitro and in vivo. Interestingly, despite its benefits in suppressing tumor growth, anti-estrogenic endocrine therapy decreases EVL expression and increases local invasion in patients. Our results highlight the dichotomous effects of estrogen on tumor progression and suggest that, in contrast to its established role in promoting growth of ER+ tumors, estrogen has a significant role in suppressing invasion through actin cytoskeletal remodeling.

20 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DUDiana J Uribe
Diana J Uribe
EMEdward K Mandell
Edward K Mandell
AWAdam Watson
Adam Watson
JMJesse D Martinez
Jesse D Martinez
JLJonathan A Leighton
Jonathan A Leighton
CRCarla Rothlin
Carla Rothlin
The receptor tyrosine kinases (RTKs) TYRO3, AXL and MERTK (TAM) have well-described oncogenic functions in a number of cancers. Notwithstanding, TAM RTKs are also potent and indispensable inhibitors of inflammation. The combined deletion of Axl and Mertk in mice enhances chronic inflammation and autoimmunity, including increased inflammation in the gut and colitis-associated cancer. On the other hand, deletion of Tyro3 increases the risk of allergic responses. Therefore, the indiscriminate inhibition of these TAM RTKs could result in undesirable immunological diseases. Here we show that AXL, but not MERTK or TYRO3 expression is enhanced in late stage colorectal cancer (CRC) and AXL expression associates with a cell migration gene signature. Silencing AXL or the inhibition of AXL kinase activity significantly inhibits tumor cell migration and invasion. These results indicate that the selective inhibition of AXL alone might confer sufficient therapeutic benefit in CRC, while preserving at least some of the beneficial, anti-inflammatory effects of MERTK and TYRO3 RTKs.

16 September 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
MQMiguel Quintela-Fandino
Miguel Quintela-Fandino
BBBegoña Bermejo
Begoña Bermejo
EZEsther Zamora
Esther Zamora
FMFernando Moreno-Anton
Fernando Moreno-Anton
JGJosé Ángel García-Saénz
José Ángel García-Saénz
Ghassan (Gus) MouneimneGhassan (Gus) Mouneimne
Ghassan (Gus) Mouneimne
Purpose: Tumor progression has been linked to stiffening of the extracellular matrix caused by fibrosis. Cancer cells can be mechanically conditioned by stiff extracellular matrix, exhibiting a 1,004-gene signature [mechanical conditioning (MeCo) score]. Nintedanib has demonstrated antifibrotic activity in idiopathic pulmonary fibrosis. This study explores nintedanib’s antifibrotic effect on breast cancer outcomes. Experimental Design: We present long-term follow-up and analysis of a neoadjuvant randomized phase II trial in early HER2-negative breast cancer. Patients (N = 130) underwent a baseline biopsy and received 12 paclitaxel courses alone (control arm) or in combination with nintedanib (experimental arm). The tumor MeCo score was determined by RNA sequencing. The primary aim was to assess nintedanib’s impact on event-free survival based on MeCo scores. Results: Follow-up data were retrieved from 111 patients; 75 baseline and 24 post-run-in phase samples were sequenced. After median follow-up of 9.67 years, median event-free survival was not statistically different between arms (P = 0.37). However, in the control arm, high- versus low-MeCo patients had a statistically higher relapse risk: HR = 0.21; P = 0.0075. This risk was corrected by nintedanib in the experimental arm: HR = 0.37; P = 0.16. Nintedanib demonstrated pharmacodynamic engagement, reducing the MeCo score by 25% during the run-in phase (P < 0.01). Patients with low MeCo after run-in had the best long-term prognosis (HR = 0.087; P = 0.03). Conclusions: High MeCo is predictive of poor outcomes in HER2-negative early breast cancer, although this risk can be mitigated by nintedanib, which is able to specifically reduce MeCo.

20 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
AWAdam W Watson
Adam W Watson
AGAdam Grant
Adam Grant
SPSara S Parker
Sara S Parker
MHMichael W Harman
Michael W Harman
MRMackenzie R Roman
Mackenzie R Roman
Ghassan (Gus) MouneimneGhassan (Gus) Mouneimne
Ghassan (Gus) Mouneimne
The mechanical microenvironment of primary breast tumors plays a substantial role in promoting tumor progression. While the transitory response of cancer cells to pathological stiffness in their native microenvironment has been well described, it is still unclear how mechanical stimuli in the primary tumor influence distant, late-stage metastatic phenotypes across time and space in absentia. Here, we show that primary tumor stiffness promotes stable, non-genetically heritable phenotypes in breast cancer cells. This mechanical memory instructs cancer cells to adopt and maintain increased cytoskeletal dynamics, traction force, and 3D invasion in vitro, in addition to promoting osteolytic bone metastasis in vivo. Furthermore, we established a mechanical conditioning (MeCo) score comprised of mechanically-regulated genes as a global gene expression measurement of tumor stiffness response. Clinically, we show that a high MeCo score is strongly associated with bone metastasis in patients. Using a discovery approach, we mechanistically traced mechanical memory in part to ERK-mediated mechanotransductive activation of RUNX2, an osteogenic gene bookmarker and bone metastasis driver. The combination of these RUNX2 traits permits the stable transactivation of osteolytic target genes that remain upregulated after cancer cells disseminate from their activating microenvironment in order to modify a distant microenvironment. Using genetic, epigenetic, and functional approaches, we were able to simulate, repress, select and extend RUNX2-mediated mechanical memory and alter cancer cell behavior accordingly. In concert with previous studies detailing the influence of biochemical properties of the primary tumor stroma on distinct metastatic phenotypes, our findings detailing the influence of biomechanical properties support a generalized model of cancer progression in which the integrated properties of the primary tumor microenvironment govern the secondary tumor microenvironment, i.e., soil instructs soil.